ZIOPHARM Oncology

Alaunos Therapeutics, Inc. is a biopharmaceutical company and clinical-stage oncology-focused cell therapy company, which engages in the development of adoptive TCR engineered T-cell therapies, or TCR-T, designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs. Its pipeline includes Library TCR-T cell and mblL-15 TCR-T cell Therapy. The company was founded in 2003 and is headquartered in Houston, TX.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BOSTON, June  15, 2020  (GLOBE NEWSWIRE) --  Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq: ZIOP), today announced the appointment of renowned oncology and immunotherapy pioneer, Carl June, M.D., as Chairman of its newly formed Scientific Advisory Board (SAB). Dr. June is recognized in the oncology field for his groundbreaking work in the development and commercialization of gene therapy and T-cell therapies. The SAB will provide strategic counsel to guide the efficient development of Ziopharm’s innovative technologies and pipeline of immunotherapies to treat the many patients with solid tumors.

Ziopharm Oncology Appoints Carl June, M.D., as Chairman of Scientific Advisory Board

BOSTON, June  12, 2020  (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to participate in a webcast panel session titled Cell Therapy: Promise of the Next Generation at the Raymond James Human Healthcare Innovation Conference on Wednesday, June 17, 2020, at 12:00 p.m. ET. The virtual panel will be hosted by equity research analysts Dane Leone and David Novak.

Ziopharm Oncology to Participate in Cell Therapy Panel at the Raymond James Human Healthcare Innovation Conference on June 17, 2020

Dr. David Mauney stepping down as President; Remains a consultant to the Company Dr. David Mauney stepping down as President; Remains a consultant to the Company

Ziopharm Oncology Announces Management Transition

ZIOPHARM Oncology, Inc. (ZIOP) CEO Laurence Cooper on Q1 2020 Results - Earnings Call Transcript

ZIOPHARM Oncology, Inc. (ZIOP) CEO Laurence Cooper on Q4 2019 Results - Earnings Call Transcript

Ziopharm Secondary, And Other News: The Good, Bad And Ugly Of Biopharma

The small-cap pharmaceutical company announced the pricing of a public stock offering.

Here's Why Ziopharm Oncology Fell as Much as 14.0% Today

BOSTON, Feb.  05, 2020  (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq:ZIOP) today announced the pricing of an underwritten public offering of 27,826,086 shares of its common stock at a public offering price of $3.25 per share. Ziopharm has granted the underwriters a 30-day option to purchase up to an additional 4,173,912 shares of common stock at the public offering price, less the underwriting discounts and commissions. The gross proceeds to Ziopharm before deducting underwriting discounts and commissions and estimated offering expenses payable by Ziopharm, are expected to be approximately $90.4 million, excluding any exercise of the underwriters’ option to purchase additional shares.

Ziopharm Oncology Announces Pricing of Public Offering of Common Stock

BOSTON, Feb.  04, 2020  (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq:ZIOP) today announced that it intends to offer and sell shares of its common stock in an underwritten registered public offering. All of the shares in the offering are to be sold by Ziopharm. Ziopharm also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the number of shares of common stock offered in the public offering at the public offering price, less underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Ziopharm Oncology Announces Proposed Public Offering of Common Stock

Ziopharm’s TCR approach targets solid tumors by recognizing neoantigens unique to each patient's cancer.

Ziopharm Stands Out, But Still Riskier Than Cellectis

– Encouraging long-term outcome data after infusion of Sleeping Beauty-modified CAR-T published in Blood –

Ziopharm Oncology Announces Recent Publications in  Peer-Reviewed Scientific Journals

Investors need to pay close attention to ZIOPHARM Oncology (ZIOP) stock based on the movements in the options market lately.

Options Traders Expect Huge Moves in ZIOPHARM Oncology (ZIOP) Stock

BOSTON, Dec.  09, 2019  (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP) today reported that the Company granted a new employee an option to purchase an aggregate of 65,000 shares of Ziopharm’s common stock effective November 21, 2019. The options were granted as an inducement material to such employee’s entering into employment with Ziopharm in accordance with Nasdaq Listing Rule 5635(c)(4).

Ziopharm Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Akcea Therapeutics

AMAG Pharmaceuticals

Axsome Therapeutics

Cronos Group

Eidos Therapeutics Inc

Heron Therapeutics

Ligand Pharmaceuticals

Paratek Pharma

PolarityTE Inc

Viking Therapeutics

Intrexon

Biotech investment is risk fraught. Most biotech stocks are at the mercy of binary events, which serve as make-or-break catalysts.

12 Biotech Stocks Primed For A Short Squeeze

– Controlled IL-12 evaluated as monotherapy in an expanded number of patients reinforced favorable safety profile and initial data consistent with immune-mediated anti-tumor effects –

Ziopharm Oncology Presents Encouraging Clinical Data for Controlled IL-12 for the Treatment of Recurrent Glioblastoma at the 2019 Society for Neuro-Oncology Annual Meeting

ZIOPHARM Oncology, Inc. (ZIOP) CEO Dr.

–  Accelerates capability for TCR library expansion of T-cell receptors (TCRs) targeting neoatigens, including in hotspots –

Ziopharm Oncology and MD Anderson Cancer Center Announce New R&D Agreement to Expand TCR-T Program

– Industry veteran with 20+ years of global oncology drug development leadership –   

Ziopharm Oncology Names Drug Development Leader Dr. Chris Bowden to Board of Directors

ZIOPHARM declined 30% despite the absence of company-specific negative news.

Ziopharm Oncology: Attractive Entry Level After A Recent Pullback

BOSTON, Aug.  28, 2019  (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP) today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, will participate in a webcast fireside chat at the Morgan Stanley 17th Annual Global Healthcare Conference in New York on September 9, 2019, beginning at 4:15 p.m. Eastern Time.

Ziopharm Oncology to Participate in the Morgan Stanley  17th Annual Global Healthcare Conference

ZIOPHARM Oncology, Inc. (ZIOP) CEO Laurence Cooper on Q2 2019 Results - Earnings Call Transcript

Adverum Biotechnologies

ArQule

Diebold Nixdorf

Enphase Energy

Roku

Pfizer

Small-cap stocks have under-performed their large cap peers in 2019, but these 7 small-cap stocks have each more than tripled this year.

The 7 Top Small-Cap Stocks Of 2019

Riding the waves of CAR-T innovation, Ziopharm Oncology is substantially rewarding shareholders while delivering hopes to patients afflicted by deadly tumors.

Ziopharm: Awakening The Sleeping Beauty CAR-T

ZIOPHARM Oncology, Inc. (ZIOP) CEO Laurence Cooper on Q1 2019 Results - Earnings Call Transcript

ZIOPHARM Oncology Inc.  shares  were seeing activity Monday after the thinly traded small biotech announced that it secured a Fast Track designation for its lead asset.

News for ZIOPHARM Oncology Stock (ZIOP)